ArticleAsian journal of andrology2026
Testicular sperm aspiration enhances fertilization rates in MMAF patients undergoing ICSI: a retrospective cohort study.
Article in Asian journal of andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple morphological abnormalities of the sperm flagella (MMAF) compromise intracytoplasmic sperm injection (ICSI) outcomes. Testicular sperm aspiration (TESA) may be beneficial, but its impact on early embryonic development and pregnancy in MMAF remains uncertain. This study evaluated the effect of TESA on fertilization, cleavage, on-time Day-3 embryo development, and clinical pregnancy and explored modification by female age and MMAF genotype. In this retrospective cohort, 196 MMAF patients undergoing ICSI (January 2019-December 2024) without female-factor infertility were analyzed: TESA group ( n = 65) versus non-TESA group ( n = 131). Only fresh embryo transfer cycles were included. Outcomes were fertilization, cleavage, on-time Day-3 embryo development, and pregnancy. Multivariable regression was complemented by inverse probability of treatment weighting, propensity score matching, and stratified analyses by female age and genotype. Robustness was examined using bootstrap resampling and outlier-sensitivity analyses. Notably, TESA was associated with higher fertilization rates (adjusted coefficient: +5.63%, P = 0.022; inverse probability of treatment weighting average treatment effect [IPTW-ATE]: +5.9%, P = 0.022; Cohen's d: 0.371). Cleavage gains were smaller (IPTW-ATE: +3.8%, P = 0.013; Cohen's d: 0.246) and method-sensitive. No significant differences were found for on-time Day-3 development or pregnancy; power was limited for these endpoints. TESA mostly improved fertilization in women aged 30-35 years (IPTW-ATE: +9.5%, P = 0.017) and cleavage in genotype-negative patients (IPTW-ATE: +10.1%, P = 0.012). Propensity models showed good balance (area under the receiver operating characteristic curve: 0.638, and standardized differences <0.1); power was adequate for fertilization (0.825). Overall, TESA is associated with higher fertilization rates in MMAF-ICSI, with modest and method-sensitive evidence for cleavage, supporting selective use. Prospective, multi-center validation is needed. Limited downstream effects suggest a role primarily at early stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.